Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pegylated liposomal doxorubicin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: pegylated liposomal doxorubicin. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-003091-77 Sponsor Protocol Number: B9991009 Start Date*: 2016-03-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone to In Patien...
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) AT (Completed) ES (Completed) GR (Completed) IE (Completed) NL (Completed) FR (Completed) PL (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003324-36 Sponsor Protocol Number: NT14035-3/2013 Start Date*: 2013-11-07
    Sponsor Name:Charles University in Prague, Faculty of Medicine in Hradec Králové
    Full Title: Kinetically guided removal of plazma pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer.
    Medical condition: Primary aim: enhanced therapeutic benefit of liposomal doxorubicin - a drug indicated for ovarian cancer resistant to chemotherapy with the first line drugs. This approach can be considered a model...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002399-40 Sponsor Protocol Number: Start Date*: 2005-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.
    Medical condition: Recurrent ovarian cancer Cytologic / histologic diagnosis of stage IC-IV ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004690-14 Sponsor Protocol Number: NA Start Date*: 2021-01-12
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026311 Malignant neoplasm of ovary and other uterine adnexa LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061535 Ovarian neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002736-28 Sponsor Protocol Number: GINECO-BR106 Start Date*: 2007-09-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old wi...
    Medical condition: Breast cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005181-20 Sponsor Protocol Number: CEPO906A2303 Start Date*: 2006-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/r...
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include yo...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) FI (Completed) DK (Completed) HU (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004925-64 Sponsor Protocol Number: Cola Start Date*: 2008-05-28
    Sponsor Name:HSK Research GmbH
    Full Title: A Phase II Controlled Study of pegylated liposomal Doxorubicin (PLD, CAELYX) and Carboplatin for the Preoperative Treatment of Advanced Breast Cancer
    Medical condition: A PLD and Carboplatin based neoadjuvant treatment regimen with less cardiotoxicity (as compared to other anthracyclines) and generally reduced side effects is of interest not only for breast cancer...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001117-17 Sponsor Protocol Number: GEICAM/2004-05 Start Date*: 2005-11-30
    Sponsor Name:GEICAM (GRUPO ESPAÑOL DE INVESTIGACION EN CANCER DE MAMA)
    Full Title: PHASE IV.II, CLINICAL TRIAL, WITH THE COMBINATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CYCLOPHOSPHAMIDE AND TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH OVEREXPRES...
    Medical condition: PATIENTS WITH METASTATIC BREAST CANCER AND OVEREXPERSSION OF HER2NEU
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001375-38 Sponsor Protocol Number: RNOP-09 Start Date*: 2006-08-30
    Sponsor Name:Klinik und Poliklinik für Neurologie der Universität Regensburg am Bezirksklinikum
    Full Title: Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV
    Medical condition: newly diagnosed Glioblastoma multiforme WHO Grade IV
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005251-39 Sponsor Protocol Number: PM1183-C-004-14 Start Date*: 2015-06-15
    Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal
    Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)
    Medical condition: Platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) AT (Completed) BE (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007799-13 Sponsor Protocol Number: 48226787 Start Date*: 2009-03-05
    Sponsor Name:Vejle Sygehus
    Full Title: Panitumumab (Vectibix®) og liposomal doxorubicin (Caelyx®) til platinresistent epithelial ovariecancer uden KRAS mutationer
    Medical condition: Platinresistent epithelial ovariecancer uden KRAS mutationer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Ongoing) AT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000971-26 Sponsor Protocol Number: RHF-CAELYX-002 Start Date*: 2016-04-04
    Sponsor Name:Charles University in Prague, Medical Faculty
    Full Title: Liposoms (drug delivery systems) in kinetically guided therapy of ovarian platinum-resistant carcinoma with doxorubicin using plasmafiltration
    Medical condition: Chemotherapy of ovarian platinum-resistant carcinoma
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000245-55 Sponsor Protocol Number: AGO-GYN 7 Start Date*: 2008-06-24
    Sponsor Name:GYN Research GmbH
    Full Title: Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Medical condition: Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000277-72 Sponsor Protocol Number: ARRAY-162-311 Start Date*: 2013-09-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or...
    Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002172-16 Sponsor Protocol Number: PM1183-B-002-11 Start Date*: 2011-10-18
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients.
    Medical condition: Platinum-Resistant / Refractory Advanced Ovarian Cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024067-41 Sponsor Protocol Number: COLTONE Start Date*: 2011-04-28
    Sponsor Name:F.A.R.O. FONDAZIONE PER LE ATTIVITA' DI RICERCA IN ONCOLOGIA
    Full Title: Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis...
    Medical condition: Elderly patients with diagnosis of early breast Cancer candidate to adjuvant chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000265-67 Sponsor Protocol Number: APR-486 Start Date*: 2017-08-01
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
    Medical condition: Platinum-resistant high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022949-17 Sponsor Protocol Number: ET-D-009-10 Start Date*: 2010-10-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of las...
    Medical condition: Advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) NL (Ongoing) DK (Completed) DE (Completed) ES (Completed) AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007622-22 Sponsor Protocol Number: D0810C00012 Start Date*: 2008-08-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Lipo...
    Medical condition: Advanced BRCA1 or BRCA2 associated ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SE (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 22 19:06:46 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA